Maxwell Skor
Stock Analyst at Morgan Stanley
Total Price Targets
7
Stocks Covered
7
Sectors
Healthcare
Most Recent
Mar 13, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Maxwell Skor
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| SANA | Sana Biotechnology, Inc. | $12.00 | $3.30 | +263.6% | 1 | Mar 13, 2026 |
| MNPR | Monopar Therapeutics Inc. | $115.00 | $53.02 | +116.9% | 1 | Jan 9, 2026 |
| CYTK | Cytokinetics, Incorporated | $90.00 | $64.40 | +39.8% | 1 | Jan 8, 2026 |
| RARE | Ultragenyx Pharmaceutical Inc. | $50.00 | $24.79 | +101.7% | 1 | Jan 8, 2026 |
| INSM | Insmed Incorporated | $157.00 | $133.75 | +17.4% | 1 | Jan 8, 2026 |
| PHVS | Pharvaris N.V. | $41.00 | $29.04 | +41.2% | 1 | Dec 4, 2025 |
| IVVD | Invivyd, Inc. | $10.00 | $1.53 | +553.6% | 1 | Mar 26, 2024 |
Recent Activity
- Mar 13, 2026— Set$12.00price target onSANA(Sana Biotechnology, Inc.)
- Jan 9, 2026— Set$115.00price target onMNPR(Monopar Therapeutics Inc.)
- Jan 8, 2026— Set$90.00price target onCYTK(Cytokinetics, Incorporated)
- Jan 8, 2026— Set$50.00price target onRARE(Ultragenyx Pharmaceutical Inc.)
- Jan 8, 2026— Set$157.00price target onINSM(Insmed Incorporated)
- Dec 4, 2025— Set$41.00price target onPHVS(Pharvaris N.V.)
- Mar 26, 2024— Set$10.00price target onIVVD(Invivyd, Inc.)
Frequently Asked Questions
Who is Maxwell Skor?
Maxwell Skor is a stock analyst at Morgan Stanley covering 7 stocks primarily in Healthcare. They have issued 7 price targets since Mar 26, 2024.
What stocks does Maxwell Skor cover?
Maxwell Skor currently covers 7 stocks, including SANA, MNPR, CYTK, RARE, INSM.
What is Maxwell Skor's latest price target?
Maxwell Skor's most recent price target was $12.00 on SANA (Sana Biotechnology, Inc.), set on Mar 13, 2026.
What is Maxwell Skor's highest price target?
Maxwell Skor's highest issued price target is $157.00 on INSM, set on Jan 8, 2026.
More Analysts at Morgan Stanley
Coverage based on publicly published price targets. Not investment advice.